CoChat

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006)

Open access
Hjorth‐Hansen, Henrik, Stenke, Leif, Söderlund, Stina, Dreimane, Arta, Ehrencrona, Hans, Gedde‐Dahl, Tobias, Gjertsen, Bjørn Tore, Höglund, Martin, Koskenvesa, Perttu, Lotfi, Kourosh, Majeed, Waleed, Markevärn, Berit, Ohm, Lotta, Olsson‐Strömberg, Ulla, Remes, Kari, Suominen, Merja, Simonsson, Bengt, Porkka, Kimmo, Mustjoki, Satu, Richter, Johan, the Nordic CML Study Group (NCMLSG) · 2015 · European Journal of Haematology
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention‐to‐treat analysis with 36 months follow‐up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3 months in 36% vs. 8% (P = 0.02), at 12 months in 81% vs. 46% (P = 0.02) and at 18 months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6 months onwards, reaching 61% vs. 21% (P < 0.05) at 36 months. Sixty‐four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML‐related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment‐free remission after treatment discontinuation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ejh.12423

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 63

Metadata

Authors
Hjorth‐Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde‐Dahl, T., Gjertsen, B. T., Höglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevärn, B., Ohm, L., Olsson‐Strömberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., Richter, J., & the Nordic CML Study Group (NCMLSG)
Venue
European Journal of Haematology
Publisher
Wiley
Published
2014-09-13
Volume
94
Issue
3
Pages
243-250
ISSN
  • 0902-4441 (ISSN-L)
  • 1600-0609
OpenAlex
W2119900325
Cited by
63
References
1
FWCI
5.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006). https://app.cochat.ai/papers/10.1111/ejh.12423
The paper
Hjorth‐Hansen, H., Stenke, L., Söderlund, S., Dreimane, A., Ehrencrona, H., Gedde‐Dahl, T., Gjertsen, B. T., Höglund, M., Koskenvesa, P., Lotfi, K., Majeed, W., Markevärn, B., Ohm, L., Olsson‐Strömberg, U., Remes, K., Suominen, M., Simonsson, B., Porkka, K., Mustjoki, S., . . . the Nordic CML Study Group (NCMLSG). (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (Nord CML 006). European Journal of Haematology. https://doi.org/10.1111/ejh.12423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.